NUDT15 Haplotypes and Diplotypes Predict Thiopurine-Induced Leukopenia and the Influence of Prolonged Exposure to Azathioprine on Hematologic Indices in Patients with Inflammatory Bowel Diseases
Table 1
Clinical characteristics and adverse events of patients.
Characteristics
NUDT15 wild type (n = 58)
NUDT15 mutant type (n = 22)
Total (n = 80)
value
Sex (male/female)
40/18
15/7
55/25
0.946
Age (yr), M(R)
31.5 (17–78)
30.5 (18–58)
31 (17–78)
0.385
Disease type
CD/UC
52/6
21/1
73/7
0.667
AZA final dosage (mg·kg−1·d−1), M(R)
1.36 (0.56–2.5)
1.02 (0.35–2.0)
1.23 (0.35–2.5)
0.013
AZA duration (wk), M(R)
48 (4–288)
46 (1–336)
48 (1–336)
0.159
Concomitant therapy
46
14
60
0.148
5-ASA
13
1
14
0.097
Steroids
28
8
36
0.339
IFX
7
6
13
0.171
Thalidomide
10
1
11
0.274
Montreal classification of CD
52
21
73
0.667
Age range at diagnosis (A1/A2/A3)
0/38/14
0/17/4
0/55/18
0.48
Disease location (L1/L2/L3/L4)
21/3/28/7
4/1/16/2
25/4/44/9
0.305
Disease behavior (B1/B2/B3/P)
26/22/6/28
14/5/2/9
40/27/8/37
0.485
Disease extension of UC (E1/E2/E3)
0/0/6
0/0/1
0/0/7
Adverse events (%)
16 (27.6)
15 (68.1)
31 (38.8)
0.002
Leukopenia
9 (15.5)
12 (54.6)
21 (26.2)
4×10−4
Hepatotoxicity
1 (1.7)
0 (0)
1 (1.3)
1
Acute pancreatitis
1 (1.7)
1 (4.5)
2 (2.5)
0.477
Rash
3 (5.1)
1 (4.5)
4 (5.0)
1
Gastrointestinal side effects
2 (3.4)
0 (0)
2 (2.5)
1
Alopecia
0 (0)
1 (4.5)
1 (1.3)
0.275
The values in bold in the table are less than 0.05.
